Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Tajana, Silovski"'
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 3, Pp 413-423 (2024)
Abstract Background and Objective Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab combined with taxane-based chemotherapy (Cht) has been the standard first-line treatment for HER2-positive metastatic brea
Externí odkaz:
https://doaj.org/article/7d6de2cac57543c2872c68778f021167
Autor:
Dubravko Forčić, Karmen Mršić, Melita Perić-Balja, Tihana Kurtović, Snježana Ramić, Tajana Silovski, Ivo Pedišić, Ivan Milas, Beata Halassy
Publikováno v:
Vaccines, Vol 12, Iss 9, p 958 (2024)
Intratumoural oncolytic virotherapy may have promise as a means to debulk and downstage inoperable tumours in preparation for successful surgery. Here, we describe the unique case of a 50-year-old self-experimenting female virologist with locally rec
Externí odkaz:
https://doaj.org/article/fffd39ceb5014a74baa397874826022b
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 12, p 6658 (2024)
Triple-negative breast cancer (TNBC) remains one of the most challenging subtypes since it is initially characterized by the absence of specific biomarkers and corresponding targeted therapies. Advances in methodology, translational informatics, geno
Externí odkaz:
https://doaj.org/article/dc36b073b9c944a0a26f4d8f6f5a2e4c
Autor:
Lu Turković, Natan Koraj, Zvonimir Mlinarić, Tajana Silovski, Slaven Crnković, Miranda Sertić
Publikováno v:
Heliyon, Vol 9, Iss 8, Pp e18880- (2023)
Cyclin D dependent kinase 4 and 6 (CDK 4/6) inhibitors are novel anticancer drugs used in therapeutic combinations with endocrine therapy for breast cancer treatment. Their determination in patient plasma is of high interest as a prerequisite for pos
Externí odkaz:
https://doaj.org/article/8319d600be9c4c8f9cde7e7d0cea197f
Autor:
Lu Turković, Dragana Mutavdžić Pavlović, Zvonimir Mlinarić, Anamarija Skenderović, Tajana Silovski, Miranda Sertić
Publikováno v:
Pharmaceuticals, Vol 16, Iss 10, p 1445 (2023)
In the development of bioanalytical LC-MS methods for the determination of drugs in plasma samples in a clinical setting, adequate sample preparation is of utmost importance. The main goals are to achieve the selective extraction of the analytes of i
Externí odkaz:
https://doaj.org/article/33f64e0732434da3a3ae9d2477aabf9a
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 9, p 8206 (2023)
Despite the great progress made in the understanding of the biological behavior of certain types of invasive breast cancer, there is still no single histological or molecular classification that encompasses such diversity and accurately predicts the
Externí odkaz:
https://doaj.org/article/d8d5cfb68a1a4073ae99970739477f73
Publikováno v:
Acta Clinica Croatica, Vol 59., Iss 4., Pp 761-764 (2020)
Oxaliplatin is part of the standard chemotherapy regimens for treating colorectal carcinoma. Pulmonary fibrosis is a serious but rare side effect of oxaliplatin treatment, which resulted in patient death in more than half of the reported cases. The
Externí odkaz:
https://doaj.org/article/929deec224cd4548a79d0c278616d434
Publikováno v:
Liječnički vjesnik, Vol 145, Iss Supp 2, Pp 86-86 (2023)
Immunotherapy is an evolving and promising cancer treatment proven to significantly prolong survival in a multitude of oncological diseases. Nivolumab, a monoclonal antibody to the PD-1 receptor, is an immunotherapy used in the treatment of several c
Externí odkaz:
https://doaj.org/article/35cd0cfcc598412dbea5a7f8291d5288
Autor:
Frankie A. Holmes, Beverly Moy, Suzette Delaloge, Stephen K.L. Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H. Barrios, Tajana Silovski, Robert Šeparović, Anna Bashford, Angel Guerrero Zotano, Neelima Denduluri, Debra Patt, Erhan Gokmen, Ira Gore, John W. Smith, Sibylle Loibl, Norikazu Masuda, Zorica Tomašević, Katarina Petráková, Daniel DiPrimeo, Alvin Wong, Miguel Martin, Arlene Chan
Publikováno v:
European Journal of Cancer. 184:48-59
ExteNET showed that neratinib, an irreversible pan-HER tyrosine ki- nase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved inva- sive disease-free survival in women with early-stage HER2-positive breast cancer. We rep
Autor:
Ingrid Belac Lovasić, Martina Bašić Koretić, Paula Podolski, Natalija Dedić Plavetić, Tajana Silovski, Stjepko Pleština, Marijana Jazvić, Željko Soldić, Robert Šeparović, Ana Tečić Vuger, Lidija Beketić Orešković, Ilijan Tomaš, Josipa Flam, Branka Petrić Miše, Marija Ban, Vesna Telesmanić Dobrić, Anuška Budisavljević, Josipa Jović Zlatović, Marijo Nalbani, Željko Vojnović, Zlatko Marušić, Snježana Tomić, Manuela Avirović, Bojan Štambuk, Danko Velimir Vrdoljak, Maja Prutki, Boris Brkljačić, Tade Tadić, Davor Mijatović, Zdenko Stanec, Ivan Milas, Eduard Vrdoljak
Publikováno v:
Liječnički vjesnik, Vol 144, Iss 9-10, Pp 395-305 (2022)
Breast cancer is the most common cancer in women, which can be diagnosed early through screening, early detection and through education. When diagnosed early, it can be successfully treated. Treatment modalities include surgery, chemotherapy, radioth
Externí odkaz:
https://doaj.org/article/8b47de584e464a4896b007bbb6197d58